Alirocumab (Praluent) to Get   New Indication in Europe Alirocumab (Praluent) to Get   New Indication in Europe

The European CHMP has also started a review of bleeding risks with the new oral anticoagulant agents and is reexamining its previous recommendation against use of omega 3 fatty acids after MI.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news